This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy Drugs. This report contains market size and forecasts of Duchenne Muscular Dystrophy Drugs in global, including the following market information:
Global Duchenne Muscular Dystrophy Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Duchenne Muscular Dystrophy Drugs market was valued at US$ 1041.1 million in 2022 and is projected to reach US$ 7464.7 million by 2029, at a CAGR of 32.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Molecular-based Therapies Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Duchenne Muscular Dystrophy Drugs include Biogen, Roche, Daiichi Sankyo, Pfizer, Cumberland Pharmaceuticals, Santhera Pharmaceuticals, Taiho Pharmaceutical, Teijin Pharma and Akashi Therapeutics, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Duchenne Muscular Dystrophy Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Duchenne Muscular Dystrophy Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Duchenne Muscular Dystrophy Drugs Market Segment Percentages, by Type, 2022 (%)
Molecular-based Therapies
Steroid Therapy
Other
Global Duchenne Muscular Dystrophy Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Duchenne Muscular Dystrophy Drugs Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Duchenne Muscular Dystrophy Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Duchenne Muscular Dystrophy Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Duchenne Muscular Dystrophy Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Duchenne Muscular Dystrophy Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Biogen
Roche
Daiichi Sankyo
Pfizer
Cumberland Pharmaceuticals
Santhera Pharmaceuticals
Taiho Pharmaceutical
Teijin Pharma
Akashi Therapeutics
Sarepta Therapeutics
BioMarin
Fibrogen Inc
Nobelpharma Co. Ltd
Eloxx Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Duchenne Muscular Dystrophy Drugs, market overview.
Chapter 2: Global Duchenne Muscular Dystrophy Drugs market size in revenue.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Duchenne Muscular Dystrophy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Duchenne Muscular Dystrophy Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Duchenne Muscular Dystrophy Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Duchenne Muscular Dystrophy Drugs Overall Market Size
2.1 Global Duchenne Muscular Dystrophy Drugs Market Size: 2022 VS 2029
2.2 Global Duchenne Muscular Dystrophy Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Duchenne Muscular Dystrophy Drugs Players in Global Market
3.2 Top Global Duchenne Muscular Dystrophy Drugs Companies Ranked by Revenue
3.3 Global Duchenne Muscular Dystrophy Drugs Revenue by Companies
3.4 Top 3 and Top 5 Duchenne Muscular Dystrophy Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Duchenne Muscular Dystrophy Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Duchenne Muscular Dystrophy Drugs Players in Global Market
3.6.1 List of Global Tier 1 Duchenne Muscular Dystrophy Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Duchenne Muscular Dystrophy Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Duchenne Muscular Dystrophy Drugs Market Size Markets, 2022 & 2029
4.1.2 Molecular-based Therapies
4.1.3 Steroid Therapy
4.1.4 Other
4.2 By Type - Global Duchenne Muscular Dystrophy Drugs Revenue & Forecasts
4.2.1 By Type - Global Duchenne Muscular Dystrophy Drugs Revenue, 2018-2023
4.2.2 By Type - Global Duchenne Muscular Dystrophy Drugs Revenue, 2024-2029
4.2.3 By Type - Global Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Duchenne Muscular Dystrophy Drugs Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Duchenne Muscular Dystrophy Drugs Revenue & Forecasts
5.2.1 By Application - Global Duchenne Muscular Dystrophy Drugs Revenue, 2018-2023
5.2.2 By Application - Global Duchenne Muscular Dystrophy Drugs Revenue, 2024-2029
5.2.3 By Application - Global Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Duchenne Muscular Dystrophy Drugs Market Size, 2022 & 2029
6.2 By Region - Global Duchenne Muscular Dystrophy Drugs Revenue & Forecasts
6.2.1 By Region - Global Duchenne Muscular Dystrophy Drugs Revenue, 2018-2023
6.2.2 By Region - Global Duchenne Muscular Dystrophy Drugs Revenue, 2024-2029
6.2.3 By Region - Global Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Duchenne Muscular Dystrophy Drugs Revenue, 2018-2029
6.3.2 US Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.3.3 Canada Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.3.4 Mexico Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Duchenne Muscular Dystrophy Drugs Revenue, 2018-2029
6.4.2 Germany Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.4.3 France Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.4.4 U.K. Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.4.5 Italy Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.4.6 Russia Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.4.8 Benelux Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Duchenne Muscular Dystrophy Drugs Revenue, 2018-2029
6.5.2 China Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.5.3 Japan Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.5.4 South Korea Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.5.6 India Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Duchenne Muscular Dystrophy Drugs Revenue, 2018-2029
6.6.2 Brazil Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.6.3 Argentina Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Duchenne Muscular Dystrophy Drugs Revenue, 2018-2029
6.7.2 Turkey Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.7.3 Israel Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
6.7.5 UAE Duchenne Muscular Dystrophy Drugs Market Size, 2018-2029
7 Duchenne Muscular Dystrophy Drugs Companies Profiles
7.1 Biogen
7.1.1 Biogen Company Summary
7.1.2 Biogen Business Overview
7.1.3 Biogen Duchenne Muscular Dystrophy Drugs Major Product Offerings
7.1.4 Biogen Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2018-2023)
7.1.5 Biogen Key News & Latest Developments
7.2 Roche
7.2.1 Roche Company Summary
7.2.2 Roche Business Overview
7.2.3 Roche Duchenne Muscular Dystrophy Drugs Major Product Offerings
7.2.4 Roche Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2018-2023)
7.2.5 Roche Key News & Latest Developments
7.3 Daiichi Sankyo
7.3.1 Daiichi Sankyo Company Summary
7.3.2 Daiichi Sankyo Business Overview
7.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Major Product Offerings
7.3.4 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2018-2023)
7.3.5 Daiichi Sankyo Key News & Latest Developments
7.4 Pfizer
7.4.1 Pfizer Company Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Major Product Offerings
7.4.4 Pfizer Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2018-2023)
7.4.5 Pfizer Key News & Latest Developments
7.5 Cumberland Pharmaceuticals
7.5.1 Cumberland Pharmaceuticals Company Summary
7.5.2 Cumberland Pharmaceuticals Business Overview
7.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Major Product Offerings
7.5.4 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2018-2023)
7.5.5 Cumberland Pharmaceuticals Key News & Latest Developments
7.6 Santhera Pharmaceuticals
7.6.1 Santhera Pharmaceuticals Company Summary
7.6.2 Santhera Pharmaceuticals Business Overview
7.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Major Product Offerings
7.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2018-2023)
7.6.5 Santhera Pharmaceuticals Key News & Latest Developments
7.7 Taiho Pharmaceutical
7.7.1 Taiho Pharmaceutical Company Summary
7.7.2 Taiho Pharmaceutical Business Overview
7.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Major Product Offerings
7.7.4 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2018-2023)
7.7.5 Taiho Pharmaceutical Key News & Latest Developments
7.8 Teijin Pharma
7.8.1 Teijin Pharma Company Summary
7.8.2 Teijin Pharma Business Overview
7.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Major Product Offerings
7.8.4 Teijin Pharma Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2018-2023)
7.8.5 Teijin Pharma Key News & Latest Developments
7.9 Akashi Therapeutics
7.9.1 Akashi Therapeutics Company Summary
7.9.2 Akashi Therapeutics Business Overview
7.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Major Product Offerings
7.9.4 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2018-2023)
7.9.5 Akashi Therapeutics Key News & Latest Developments
7.10 Sarepta Therapeutics
7.10.1 Sarepta Therapeutics Company Summary
7.10.2 Sarepta Therapeutics Business Overview
7.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Major Product Offerings
7.10.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2018-2023)
7.10.5 Sarepta Therapeutics Key News & Latest Developments
7.11 BioMarin
7.11.1 BioMarin Company Summary
7.11.2 BioMarin Business Overview
7.11.3 BioMarin Duchenne Muscular Dystrophy Drugs Major Product Offerings
7.11.4 BioMarin Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2018-2023)
7.11.5 BioMarin Key News & Latest Developments
7.12 Fibrogen Inc
7.12.1 Fibrogen Inc Company Summary
7.12.2 Fibrogen Inc Business Overview
7.12.3 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Major Product Offerings
7.12.4 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2018-2023)
7.12.5 Fibrogen Inc Key News & Latest Developments
7.13 Nobelpharma Co. Ltd
7.13.1 Nobelpharma Co. Ltd Company Summary
7.13.2 Nobelpharma Co. Ltd Business Overview
7.13.3 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Major Product Offerings
7.13.4 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2018-2023)
7.13.5 Nobelpharma Co. Ltd Key News & Latest Developments
7.14 Eloxx Pharmaceuticals
7.14.1 Eloxx Pharmaceuticals Company Summary
7.14.2 Eloxx Pharmaceuticals Business Overview
7.14.3 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Major Product Offerings
7.14.4 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2018-2023)
7.14.5 Eloxx Pharmaceuticals Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Duchenne Muscular Dystrophy Drugs Market Opportunities & Trends in Global Market
Table 2. Duchenne Muscular Dystrophy Drugs Market Drivers in Global Market
Table 3. Duchenne Muscular Dystrophy Drugs Market Restraints in Global Market
Table 4. Key Players of Duchenne Muscular Dystrophy Drugs in Global Market
Table 5. Top Duchenne Muscular Dystrophy Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Duchenne Muscular Dystrophy Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Duchenne Muscular Dystrophy Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Duchenne Muscular Dystrophy Drugs Product Type
Table 9. List of Global Tier 1 Duchenne Muscular Dystrophy Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Duchenne Muscular Dystrophy Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Duchenne Muscular Dystrophy Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Duchenne Muscular Dystrophy Drugs Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Duchenne Muscular Dystrophy Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Duchenne Muscular Dystrophy Drugs Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2024-2029
Table 30. Biogen Company Summary
Table 31. Biogen Duchenne Muscular Dystrophy Drugs Product Offerings
Table 32. Biogen Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. Biogen Key News & Latest Developments
Table 34. Roche Company Summary
Table 35. Roche Duchenne Muscular Dystrophy Drugs Product Offerings
Table 36. Roche Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Roche Key News & Latest Developments
Table 38. Daiichi Sankyo Company Summary
Table 39. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product Offerings
Table 40. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Daiichi Sankyo Key News & Latest Developments
Table 42. Pfizer Company Summary
Table 43. Pfizer Duchenne Muscular Dystrophy Drugs Product Offerings
Table 44. Pfizer Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Pfizer Key News & Latest Developments
Table 46. Cumberland Pharmaceuticals Company Summary
Table 47. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offerings
Table 48. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Cumberland Pharmaceuticals Key News & Latest Developments
Table 50. Santhera Pharmaceuticals Company Summary
Table 51. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offerings
Table 52. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Santhera Pharmaceuticals Key News & Latest Developments
Table 54. Taiho Pharmaceutical Company Summary
Table 55. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product Offerings
Table 56. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. Taiho Pharmaceutical Key News & Latest Developments
Table 58. Teijin Pharma Company Summary
Table 59. Teijin Pharma Duchenne Muscular Dystrophy Drugs Product Offerings
Table 60. Teijin Pharma Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. Teijin Pharma Key News & Latest Developments
Table 62. Akashi Therapeutics Company Summary
Table 63. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product Offerings
Table 64. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. Akashi Therapeutics Key News & Latest Developments
Table 66. Sarepta Therapeutics Company Summary
Table 67. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product Offerings
Table 68. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. Sarepta Therapeutics Key News & Latest Developments
Table 70. BioMarin Company Summary
Table 71. BioMarin Duchenne Muscular Dystrophy Drugs Product Offerings
Table 72. BioMarin Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn) & (2018-2023)
Table 73. BioMarin Key News & Latest Developments
Table 74. Fibrogen Inc Company Summary
Table 75. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product Offerings
Table 76. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn) & (2018-2023)
Table 77. Fibrogen Inc Key News & Latest Developments
Table 78. Nobelpharma Co. Ltd Company Summary
Table 79. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product Offerings
Table 80. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn) & (2018-2023)
Table 81. Nobelpharma Co. Ltd Key News & Latest Developments
Table 82. Eloxx Pharmaceuticals Company Summary
Table 83. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offerings
Table 84. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue (US$, Mn) & (2018-2023)
Table 85. Eloxx Pharmaceuticals Key News & Latest Developments
List of Figures
Figure 1. Duchenne Muscular Dystrophy Drugs Segment by Type in 2022
Figure 2. Duchenne Muscular Dystrophy Drugs Segment by Application in 2022
Figure 3. Global Duchenne Muscular Dystrophy Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Duchenne Muscular Dystrophy Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Duchenne Muscular Dystrophy Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue in 2022
Figure 8. By Type - Global Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2018-2029
Figure 9. By Application - Global Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2018-2029
Figure 10. By Type - Global Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2018-2029
Figure 12. By Application - Global Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2018-2029
Figure 14. By Region - Global Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2018-2029
Figure 15. By Country - North America Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2018-2029
Figure 16. US Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2018-2029
Figure 20. Germany Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 21. France Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2018-2029
Figure 28. China Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. India Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2018-2029
Figure 34. Brazil Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2018-2029
Figure 37. Turkey Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Duchenne Muscular Dystrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. Biogen Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Roche Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Pfizer Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Teijin Pharma Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. BioMarin Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
